Svaland M G, Kolmannskog F, Lillevold P E, Nordal K P, Ressem L, Berg K J
Research and Development Division, Nycomed AS, Oslo, Norway.
Acta Radiol. 1992 Sep;33(5):482-4.
Iopentol 350 mg I/ml was injected in doses of 265 to 533 mg I/kg b.w. (mean 417 mg I/kg b.w.) in 10 patients with advanced nondiabetic chronic renal failure (S-creatinine 672 +/- 259 mumol/l (mean +/- SD)). Urine (10 patients) and feces (7 patients) were collected at 24 h intervals for 5 days after the injection. The elimination of iopentol was delayed. Five days after injection a mean of 54% (range 35-79%) of the dose was recovered in urine, and 11% (0-20%) in feces. Mean elimination half-life was 28.4 h, about 14 times the half-life found in healthy volunteers. The apparent volume of distribution was 0.27 l/kg b.w., indicating distribution only to extracellular fluid. Using renal iopentol clearance as reference value, GFR was overestimated by 40 to 60% with iopentol total clearance, showing extrarenal elimination of iopentol. The difference was most pronounced in patients with low GFR. In conclusion, this study shows an extrarenal elimination of iopentol and demonstrates a substantial increase in the fecal elimination in patients with severe renal failure.
以265至533毫克碘/千克体重(平均417毫克碘/千克体重)的剂量,向10例晚期非糖尿病慢性肾衰竭患者(血清肌酐672±259微摩尔/升(平均值±标准差))注射了碘海醇350毫克碘/毫升。注射后5天,每隔24小时收集尿液(10例患者)和粪便(7例患者)。碘海醇的消除延迟。注射后5天,平均54%(范围35 - 79%)的剂量在尿液中回收,11%(0 - 20%)在粪便中回收。平均消除半衰期为28.4小时,约为健康志愿者中发现的半衰期的14倍。表观分布容积为0.27升/千克体重,表明仅分布于细胞外液。以肾脏碘海醇清除率作为参考值,碘海醇总清除率高估肾小球滤过率40%至60%,表明碘海醇存在肾外消除。这种差异在肾小球滤过率低的患者中最为明显。总之,本研究显示碘海醇存在肾外消除,并证明严重肾衰竭患者粪便消除显著增加。